<DOC>
	<DOCNO>NCT02302105</DOCNO>
	<brief_summary>Evidence justify use pelvic field lack men high risk localize prostate cancer . An additional randomized study need men potential risk nodal involvement test hypothesis use pelvic field contribute benefit observed study . This trial aim compare outcome whole pelvis RT Prostate alone RT patient High risk , non metastatic Prostate cancer Lymph nodal &gt; 20 % Primary 4 year Biochemical failure free survival Secondary Disease free survival , overall survival , Acute toxicity , Late toxicity QOL Patients randomize one two arm Arm 1 Whole pelvis radiotherapy Arm 2 Prostate radiotherapy . The Dose prescription 66 Gy 25 fraction prescribe prostate PTV Arm 2 additional 50 Gy 25 fraction nodal PTV patient Arm 1 . An overlap volume rectal-prostate interface receive 64 Gy/25 # . All patient receive hormone therapy start least 8 week prior begin radiotherapy . They continue hormone therapy later total duration 2-3 year .</brief_summary>
	<brief_title>Randomized Trial Prostate Only Pelvic RT High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion 1 . Any age accord fitness estimate Physician 2 . Physician estimate life expectancy &gt; 5 year 3 . Biopsy proven Adenocarcinoma prostate 4 . High risk prostate cancer base Staging Risk Pelvic Nodal Metastases ≥ 20 % per Roach formula ( 2/3 PSA ) + [ ( GS 6 ) x 10 ] If Gleason Score 810 Any PSA , T1 T3a N0 M0 If Gleason Score 7 PSA &gt; 15 , T1T3a N0 M0 If Gleason Score 6 PSA &gt; 30 , T1T3a N0 M0 T3bT4a N0 M0 , Any Gleason Score , Any PSA 5 . Ability receive long term hormone therapy/ Orchidectomy 6 . KPS ≥ 70 ( see appendix ) 7 . Estimated life expectancy &gt; 5 year 8 . No previous history malignancy ≤5 year 9 . No prior history therapeutic irradiation pelvis 10 . Patient willing reliable followup QOL 11 . No major co morbidity prevent radical treatment 12 . Signed study specific consent form Exclusion 1 . Any histopathology Adenocarcinoma 2 . Contraindication Pelvic Radiotherapy like Inflammatory Bowel Disorders 3 . No prior history pelvic surgery 4 . Uncontrolled diabetes 5 . Uncontrolled cardiac co morbidity 6 . Presence nodal distant metastatic disease</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>